Sudhir Paul, PhD, is Professor of Pathology and Director, Chemical Immunology Research Center at the Univ of Texas Houston Health Sciences Center. After his Ph.D. in Biochemistry from the All-India Institute of Medical Sciences in 1981, Dr. Paul was a Humboldt Fellow until 1983 at Christian Albrechts Univ, Gemany. He served as Asst Professor at Univ of Oklahoma until 1987 and then moved to Univ of Nebraska Medical Center, where he was Assoc Professor and then Professor of Pharmacology, Pathology and Anesthesiology until 1998. Dr. Paul has published more than 190 original articles, reviews and book chapters, and he has edited several books and conference proceedings on catalytic antibodies, HIV vaccination, amyloid disease and autoimmunity. He has delivered over 250 invited seminars and symposium presentations. The Paul lab discovered proteolytic antibodies and identified them as transitional molecules bridging the innate and adaptive features of humoral immunity. A single catalytic antibody molecule is reused to cleave thousands of antigen molecules, and the Paul lab is developing catalytic antibodies as a platform for treating intractable diseases. While developing immunogens for inducing catalytic antibody synthesis, they serendipitously identified an electrophilic immunogen that bound B cells covalently and corrected the immunological defect precluding synthesis of mature antibodies directed to the vulnerable, superantigenic CD4 binding site of HIV. This immunogen induced antibodies that neutralized HIV strains found world-wide. They are now exploring the potential of electrophilic immunization for vaccination against HIV. Sudhir Paul, PhD, is Professor of Pathology and Director, Chemical Immunology Research Center at the Univ of Texas Houston Health Sciences Center. After his Ph.D. in Biochemistry from the All-India Institute of Medical Sciences in 1981, Dr. Paul was a Humboldt Fellow until 1983 at Christian Albrechts Univ, Gemany. He served as Asst Professor at Univ of Oklahoma until 1987 and then moved to Univ of Nebraska Medical Center, where he was Assoc Professor and then Professor of Pharmacology, Pathology and Anesthesiology until 1998. Dr. Paul has published more than 190 original articles, reviews and book chapters, and he has edited several books and conference proceedings on catalytic antibodies, HIV vaccination, amyloid disease and autoimmunity. He has delivered over 250 invited seminars and symposium presentations. The Paul lab discovered proteolytic antibodies and identified them as transitional molecules bridging the innate and adaptive features of humoral immunity. A single catalytic antibody molecule is reused to cleave thousands of antigen molecules, and the Paul lab is developing catalytic antibodies as a platform for treating intractable diseases. While developing immunogens for inducing catalytic antibody synthesis, they serendipitously identified an electrophilic immunogen that bound B cells covalently and corrected the immunological defect precluding synthesis of mature antibodies directed to the vulnerable, superantigenic CD4 binding site of HIV. This immunogen induced antibodies that neutralized HIV strains found world-wide. They are now exploring the potential of electrophilic immunization for vaccination against HIV.

Vaccines, Immunology